Novartis Ag (NVS) EBT (QoQ) (2009 - 2023)
Novartis Ag (NVS) EBT (QoQ) (2009 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.77 Bn | 632.01 Bn | 17.26 Bn |
| 2 | AbbVie | 469.90 Bn | 463.33 Bn | 12.70 Bn |
| 3 | Merck | 377.04 Bn | 369.90 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.08 Bn | 295.39 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.74 Bn | 252.84 Bn | 12.86 Bn |
| 6 | Amgen | 236.46 Bn | 222.47 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.81 Bn | 178.63 Bn | 6.22 Bn |
| 8 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn |
| 10 | Sanofi | 55.01 Bn | 47.63 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -99.95% |
| Mar 31, 2023 | 106,054.98% |
| Dec 31, 2022 | 435.95% |
| Sep 30, 2022 | -56.95% |
| Jun 30, 2022 | -99.99% |
| Mar 31, 2022 | 570,768.40% |
| Dec 31, 2021 | 542.50% |
| Sep 30, 2021 | -73.56% |
| Jun 30, 2021 | -99.97% |
| Mar 31, 2021 | 285,109.17% |
| Dec 31, 2020 | -99.97% |
| Sep 30, 2020 | 786,653.19% |
| Jun 30, 2020 | 1,079.38% |
| Jun 30, 2019 | 427.86% |
| Mar 31, 2019 | -78.16% |
| Dec 31, 2018 | 37.32% |
| Sep 30, 2018 | -79.64% |
| Jun 30, 2018 | 1,203.19% |
| Mar 31, 2018 | -69.07% |
| Dec 31, 2017 | 8.74% |